Pfizer aims at Genzyme with Gaucher drug approval

Watch out, Genzyme. In announcing the FDA approval of its new Gaucher disease treatment Elelyso, Pfizer ($PFE) put the Sanofi ($SNY) unit firmly in its sights. Besides the usual talk about "making a d…
Read the full story: News